PerkinElmer has juggled some names at the top, replacing life sciences executive vice president John Engel with Peter Coggins, who will hold the title, president of life sciences. Engel, who oversaw PerkinElmer’s acquisition of Packard Biosciences, will now serve as executive vice president of operations at PerkinElmer.
Coggins comes to PerkinElmer from Amersham Biosciences, where he was executive vice-president of global sales and marketing. Coggins also served as chairman of the board for Amersham Japan KK, Amersham’s Japanese subsidiary. Coggins has previously worked in sales and marketing at ICN Biomedicals, Labsystems Oy, and Amersham International.
Coggins received his PhD in zoology from Chelsea College, University of London.
James Adam has been appointed chief executive officer of sprouting microarray instrument company Blizzard Genomics, in St. Paul, Minn. Adam succeeds Martin Blumenfeld, the company’s founder. Blumenfeld, who invented the company’s budget-priced microarray imager, will remain with the company as chief scientific officer and chairman of the board of directors.
Adam, who joined Blizzard Genomics as president in March 2001, founded Adam Consulting, a firm dedicated to assisting entrepreneurial organizations. He is also the former president of Ican, an internet-based provider of infectious disease information to medical professionals, and is the retired chief operating officer and chief financial officer of cancer therapy company MGI Pharma.